Animal Health

ProMed Pharma Acquires SpineThera Manufacturing Capabilities and an Option to License Intellectual Property

Retrieved on: 
Wednesday, April 3, 2024
Chemicals, Plastics, Electronic Design Automation, Manufacturing, Technology, Pharmaceutical, Physical Therapy, Medical Devices, Clinical Trials, Other Technology, Biotechnology, Science, Veterinary, Other Science, Research, Health, Engineering, CDMO, Business, Patient, CNS, ProMED-mail, CGMP, Animal Health, Sale, Business development, CMC, Acquisition, Clinical trial, Fine chemical

ProMed Pharma also obtained an option to license SpineThera’s microsphere intellectual property with the potential to sub-license to ProMed Pharma’s customers.

Key Points: 
  • ProMed Pharma also obtained an option to license SpineThera’s microsphere intellectual property with the potential to sub-license to ProMed Pharma’s customers.
  • Importantly, SpineThera is maintaining exclusive ownership of intellectual property that enables SX600.
  • With this transaction, our manufacturing team joins a highly capable CDMO, ProMed Pharma, a company we have worked with closely for many years.
  • SpineThera becomes a customer of ProMed, who will manufacture SX600 in the same cleanroom in which we previously developed the technology and manufactured clinical batches.

InstantGMP™ Welcomes Pharmsmart as a Valued Client in Expanding International Operations

Retrieved on: 
Wednesday, March 27, 2024
APVMA, Good manufacturing practice, Partnership, Animal Health, Pesticide, GMP, Good, FDA, Document management system, Medical device

CARY, N.C., March 27, 2024 /PRNewswire-PRWeb/ -- InstantGMP™, a leading provider of manufacturing software solutions ensuring Good Manufacturing Practices (GMP) and FDA compliance, proudly announces its partnership with Pharmsmart, an Australian company specializing in the development and manufacturing of Animal Health products.

Key Points: 
  • The addition of Pharmsmart to InstantGMP's clientele marks a strategic step in the company's ongoing expansion in the Asia Pacific region.
  • As InstantGMP continues to solidify its presence globally, the collaboration with Pharmsmart exemplifies a shared commitment to excellence and adherence to international quality standards.
  • Pharmsmart's decision to opt for InstantGMP™ INV software can be attributed to its comprehensive features, particularly the Equipment Management Module .
  • This ensures that Pharmsmart operators can access the system at any time and from anywhere, providing unprecedented flexibility in managing equipment and maintaining compliance.

Cryoport Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, March 12, 2024
Risk, FY, Maas, Form, Blas, Gene, Animal Health, Reproductive medicine, Form 10-K, Security (finance), Marketing, Investment, Annual report, Debt-to-GDP ratio, Cell, Medicine, MVE, Pharmaceutical industry

Total revenue for Q4 2023 was $57.3 million compared to $60.4 million for Q4 2022, a year-over-year decrease of 5% or $3.1 million.

Key Points: 
  • Total revenue for Q4 2023 was $57.3 million compared to $60.4 million for Q4 2022, a year-over-year decrease of 5% or $3.1 million.
  • Biopharma/Pharma revenue was $47.9 million, down 5% or $2.7 million for Q4 2023 compared to $50.6 million for Q4 2022.
  • Animal Health revenue was $6.8 million for Q4 2023, down 10% or $0.7 million compared to $7.5 million for Q4 2022.
  • Reproductive Medicine revenue was $2.6 million for Q4 2023, up 11% compared to $2.3 million for Q4 2022.

Patterson Companies Reports Fiscal 2024 Third Quarter Operating Results

Retrieved on: 
Wednesday, February 28, 2024
Medical Supplies, Health, Dental, General Health, Pharmaceutical, Veterinary, Acquisition, Collection, Share repurchase, Growth, Disclosure, Risk, Conference, GAAP, Consolidated, Tax, Public expenditure, Animal Health, Instrument, Patterson Companies, Internal, Public, Security (finance)

Patterson Companies, Inc. (Nasdaq: PDCO) today reported operating results for its fiscal 2024 third quarter ended January 27, 2024.

Key Points: 
  • Patterson Companies, Inc. (Nasdaq: PDCO) today reported operating results for its fiscal 2024 third quarter ended January 27, 2024.
  • Reported net income attributable to Patterson Companies, Inc. for the third quarter of fiscal 2024 was $47.7 million, or $0.52 per diluted share, compared to $53.9 million, or $0.55 per diluted share, in the third quarter of fiscal 2023.
  • Adjusted net income1 attributable to Patterson Companies, Inc., which excludes deal amortization, totaled $55.0 million for the third quarter of fiscal 2024, or $0.59 per diluted share, compared to $61.1 million, or $0.62 per diluted share, in the third quarter of fiscal 2023.
  • Patterson Companies’ fiscal 2024 third quarter conference call will start at 8:30 a.m. Eastern today.

Boehringer Ingelheim Partners with Veeva to Advance its Clinical and Regulatory Operations in Animal Health

Retrieved on: 
Wednesday, February 14, 2024
Cloud, Animal, Pharmacovigilance, Health, Safety, Boehringer Ingelheim, Animal Health, Medicine, Research, Fine chemical

PLEASANTON, Calif., Feb. 14, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Boehringer Ingelheim has selected Veeva Vault Clinical and Veeva Vault RIM applications as its technology foundation for clinical and regulatory management in its animal health business unit. By adopting unified applications on a single platform, Boehringer Ingelheim can streamline clinical execution to speed development of new medicines that help animals live healthier and happier lives.

Key Points: 
  • Global animal health leader adopts Veeva Vault Clinical and Veeva Vault RIM for greater efficiency, visibility, and speed
    PLEASANTON, Calif., Feb. 14, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Boehringer Ingelheim has selected Veeva Vault Clinical and Veeva Vault RIM applications as its technology foundation for clinical and regulatory management in its animal health business unit.
  • "Veeva Vault Clinical and Veeva Vault RIM will help us drive higher operational efficiency across functions while providing the insights for data-driven decision making," said Marcus Gravendyck, head of global regulatory affairs and pharmacovigilance, Animal Health at Boehringer Ingelheim.
  • The company will also use Vault RIM applications, including Veeva Vault Registrations , Veeva Vault Submissions , and Veeva Vault Submissions Archive for advanced regulatory processes.
  • "We're proud to partner with Boehringer Ingelheim in animal health to simplify their clinical development and regulatory processes," said Stefan Jahnecke, vice president of animal health strategy at Veeva.

Boehringer Ingelheim Partners with Veeva to Advance its Clinical and Regulatory Operations in Animal Health

Retrieved on: 
Wednesday, February 14, 2024
Cloud, Animal, Pharmacovigilance, Health, Safety, Boehringer Ingelheim, Animal Health, Medicine, Research, Fine chemical

BARCELONA, Spain, Feb. 14, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Boehringer Ingelheim has selected Veeva Vault Clinical and Veeva Vault RIM applications as its technology foundation for clinical and regulatory management in its animal health business unit. By adopting unified applications on a single platform, Boehringer Ingelheim can streamline clinical execution to speed development of new medicines that help animals live healthier and happier lives.

Key Points: 
  • Global animal health leader adopts Veeva Vault Clinical and Veeva Vault RIM for greater efficiency, visibility, and speed
    BARCELONA, Spain, Feb. 14, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Boehringer Ingelheim has selected Veeva Vault Clinical and Veeva Vault RIM applications as its technology foundation for clinical and regulatory management in its animal health business unit.
  • "Veeva Vault Clinical and Veeva Vault RIM will help us drive higher operational efficiency across functions while providing the insights for data-driven decision making," said Marcus Gravendyck, head of global regulatory affairs and pharmacovigilance, Animal Health at Boehringer Ingelheim.
  • The company will also use Vault RIM applications, including Veeva Vault Registrations , Veeva Vault Submissions , and Veeva Vault Submissions Archive for advanced regulatory processes.
  • "We're proud to partner with Boehringer Ingelheim in animal health to simplify their clinical development and regulatory processes," said Stefan Jahnecke, vice president of animal health strategy at Veeva.

ECO Animal Health Appoints Dr. Joachim Hasenmaier as Non-Executive Director

Retrieved on: 
Monday, February 12, 2024
Acquisition, The Elements of Style, Doctor of Philosophy, Boehringer Ingelheim Animal Health, Health, Growth, ECO, Veterinary medicine, MBA, AIM, Vaccine, Boehringer Ingelheim, McKinsey & Company, Animal Health, Mars, Incorporated, Ageing, Management

ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announces the appointment of Dr. Joachim Hasenmaier as a Non-Executive Director, with immediate effect.

Key Points: 
  • ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announces the appointment of Dr. Joachim Hasenmaier as a Non-Executive Director, with immediate effect.
  • Dr. Hasenmaier is a highly experienced commercial leader with more than two decades in the international animal health industry.
  • From 2001 to 2019 he held a variety of senior roles within the animal health division at Boehringer Ingelheim, concluding as member of the Board of Managing Directors responsible for the entire animal health division.
  • Dr. Andrew Jones, Chairman of ECO, commented: “On behalf of the Board, I am delighted to welcome Joachim as a Non-Executive Director to ECO.

Phibro Animal Health Corporation Reports Second Quarter Results, Updates Financial Guidance

Retrieved on: 
Wednesday, February 7, 2024
Veterinary, Health, EPS, Growth, Knowledge, GAAP, Adjustment, Animal Health, Investment, Corporation, Poultry, Vaccine, Acquisition, PAHC, Webcast

Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its second quarter ended December 31, 2023 and its updated financial guidance for the year ending June 30, 2024.

Key Points: 
  • Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its second quarter ended December 31, 2023 and its updated financial guidance for the year ending June 30, 2024.
  • Jack continued, “We expect continuing growth in our Animal Health business in the second half of the year.
  • Glenn brings over 30 years of experience in commercial and financial leadership roles, including a wealth of knowledge in the animal health industry.
  • Phibro Animal Health Corporation will host a webcast and conference call during which the Company will review its financial results and respond to questions.

Studies Validate Advantages of Administering Drugs to Pets via IntelGenx’s VetaFilm® Platform

Retrieved on: 
Monday, February 5, 2024
IGX, Dog, Animal Health, POC, Animal, TSX, Veterinarian, UPEI, Capsule, Cat, Tablet

The POC study was conducted through a research collaboration with the University Prince Edward Island (“UPEI”), one of North America’s leading veterinary universities.

Key Points: 
  • The POC study was conducted through a research collaboration with the University Prince Edward Island (“UPEI”), one of North America’s leading veterinary universities.
  • The reliable administration of medications to dogs and cats is a concern for many owners and veterinarians.
  • Forced administration of capsules, tablets and liquids may be stressful for both the pet and its owner(s).
  • “We would like to thank the esteemed clinicians and researchers at UPEI, the many pet owners, and of course the cherished dogs and cats that participated in these studies.”

2024 Feather in Her Cap and High Flyer Award Winners Named for Outstanding Achievements in Animal Health Industry

Retrieved on: 
Tuesday, January 16, 2024
Philanthropy, Health, Consumer, Women, Foundation, Veterinary, Animal Health, Woman, Osteoarthritis, Therapy, Frunevetmab, Multimedia, Female, Intellectual disability, University, Engagement, Mentorship, Dog, Pharmaceutics, Elanco, Veteran, Cat, DVM, Boehringer Ingelheim, ELAN, Doctor of Philosophy, Veterinary medicine, Highflyer, Feather, Marketing, Formulation, Inclusion, Education, Management

The Feather in Her Cap Association, Inc. and 300 industry leaders honored 11 women for their outstanding career achievements in Animal Health at the seventh annual Feather in Her Cap awards ceremony.

Key Points: 
  • The Feather in Her Cap Association, Inc. and 300 industry leaders honored 11 women for their outstanding career achievements in Animal Health at the seventh annual Feather in Her Cap awards ceremony.
  • Andrea J. Gonzales Ph.D., vice president of Global Companion Animal Therapeutics at Zoetis, Inc., (NYSE: ZTS) was awarded the 2024 Feather in Her Cap award and Katharina Bohnenblust Ph.D., senior director, head of Formulation Development at Elanco Animal Health (NYSE: ELAN) was this year’s recipient of the 2024 High Flyer award.
  • Each year, the Feather in Her Cap award winner chooses an animal-related non-profit organization to receive a $5,000 donation.
  • The nomination process will reopen in Q3 of 2024 to celebrate more outstanding women in Animal Health in 2025.